Nigella sativa oil affects glucose metabolism and lipid concentrations in patients with type 2 diabetes: A randomized, double-blind, placebo-controlled trial

被引:70
|
作者
Heshmati, Javad [1 ]
Namazi, Nazli [2 ]
Memarzadeh, Mohammad-Reza [3 ]
Taghizadeh, Mohsen [3 ]
Kolandooz, Fariba [4 ]
机构
[1] Kermanshah Univ Med Sci, Hlth Care Ctr, Kermanshah, Iran
[2] Tabriz Univ Med Sci, Fac Nutr, Nutr Res Ctr, Tabriz, Iran
[3] Barij Essence Pharmaceut Co, Ctr Res & Dev, Kashan, Iran
[4] Univ Alberta, Dept Med, Fac Med & Dent, Aboriginal & Global Hlth Res Grp, Edmonton, AB, Canada
关键词
Nigella sativa; Blood glucose; Dyslipidemias; Diabetes mellitus; Type; 2; MEDICINAL-PLANTS; URTICA-DIOICA; SEED EXTRACT; THYMOQUINONE; PEROXIDATION; PROFILE;
D O I
10.1016/j.foodres.2015.01.030
中图分类号
TS2 [食品工业];
学科分类号
0832 ;
摘要
The aim of the present study was to determine the effects of Nigella sativa (NS) oil on glucose metabolism and lipid concentrations in patients with type 2 diabetes (T2DM). In this double-blind randomized controlled clinical trial, 72 volunteer subjects at Endocrinology Clinics of Kermanshah were recruited. Participants were patients aged 30-60 years old with T2DM. They were randomly divided into intervention (n = 36) and placebo groups (n = 36) and received 3 g/day (one three times a day) NS oil or sunflower soft gel capsules for 12 weeks. At baseline and at the end of the trial, anthropometric indices, dietary intake and biochemical parameters were measured. Sixty-seven patients completed the trial (intervention n = 34, placebo n = 33). Since the data analysis was based on intention-to-treat approach, all 72 subjects (36 in each group) were included for data analysis. Two groups were similar in the baseline characteristics. After the intervention, weight and body mass index decreased in the intervention group compared to the baseline, but it was not significant between the two groups. Dietary intake in both groups changed compared to baseline. Comparison of the two groups indicated that fasting blood sugar, glycated hemoglobin, triglyceride and low density lipoprotein-cholesterol changed significantly in intervention group compared to the placebo group (p < 0.05, adjusted for confounder factors). Insulin level and insulin resistance decreased and high density lipoprotein-cholesterol increased in the intervention group, but after adjusting for confounder factors, they were not significant. Supplementation with NS oil can improve glycemic status and lipid profile in patients with T2DM. (C) 2015 Elsevier Ltd. All rights reserved.
引用
收藏
页码:87 / 93
页数:7
相关论文
共 50 条
  • [21] The effects of topical and oral Nigella sativa oil on clinical findings in knee osteoarthritis: A double-blind, randomized controlled trial
    Dolatkhah, Neda
    Afshar, Afsaneh Amirtaheri
    Sharifi, Shahrzad
    Rahbar, Mohammad
    Toopchizadeh, Vahideh
    Hashemian, Maryam
    JOURNAL OF HERBAL MEDICINE, 2022, 33
  • [22] A prospective, randomized, double-blind, placebo-controlled trial of polyphenols on the outcomes of inflammatory factors and oxidative stress in patients with type 2 diabetes mellitus
    Grabez, Milkica
    Skrbic, Ranko
    Stojiljkovic, Milos P.
    Vucic, Vesna
    Grujic, Vesna Rudic
    Jakovljevic, Vladimir
    Djuric, Dragan M.
    Surucic, Relja
    Savikinc, Katarina
    Bigovic, Dubravka
    Vasiljevic, Nada
    REVIEWS IN CARDIOVASCULAR MEDICINE, 2022, 23 (02)
  • [23] The Effects of Tocotrienols Added to Canola Oil on Microalbuminuria, Inflammation, and Nitrosative Stress in Patients with Type 2 Diabetes: A Randomized, Double-blind, Placebo-controlled Trial
    Haghighat, Neda
    Vafa, Mohammadreza
    Eghtesadi, Shahryar
    Heidari, Iraj
    Hosseini, Aghafatemeh
    Rostami, Ali
    INTERNATIONAL JOURNAL OF PREVENTIVE MEDICINE, 2014, 5 (05) : 617 - 623
  • [24] Efficacy of black seed (Nigella sativa L.) on kidney stone dissolution: A randomized, double-blind, placebo-controlled, clinical trial
    Moyaghati, Mohammad Reza Ardakani
    Yousefi, Mahdi
    Saghebi, Seyed Ahmad
    Vazin, Mahmoud Sadeghi
    Iraji, Aida
    Mosavat, Seyed Hamdollah
    PHYTOTHERAPY RESEARCH, 2019, 33 (05) : 1404 - 1412
  • [25] Nigella sativa L. for prevention of acute radiation dermatitis in breast cancer: A randomized, double-blind, placebo-controlled, clinical trial
    Rafati, Mohammadreza
    Ghasemi, Arash
    Saeedi, Majid
    Habibi, Emran
    Salehifar, Ebrahim
    Mosazadeh, Mahmood
    Maham, Monireh
    COMPLEMENTARY THERAPIES IN MEDICINE, 2019, 47
  • [26] Henagliflozin monotherapy in patients with type 2 diabetes inadequately controlled on diet and exercise: A randomized, double-blind, placebo-controlled, phase 3 trial
    Lu, Juming
    Fu, Liujun
    Li, Yan
    Geng, Jianlin
    Qin, Li
    Li, Ping
    Zheng, Hailong
    Sun, Zilin
    Li, Yanbing
    Zhang, Lihui
    Sun, Yadong
    Chen, Daoxiong
    Qin, Guijun
    Lu, Weiping
    Guo, Yushan
    Zhang, Yuwei
    Liu, Haiyan
    Zhang, Tao
    Zou, Jianjun
    DIABETES OBESITY & METABOLISM, 2021, 23 (05) : 1111 - 1120
  • [27] Hesperidin Supplementation Alleviates Oxidative DNA Damage and Lipid Peroxidation in Type 2 Diabetes: A Randomized Double-Blind Placebo-Controlled Clinical Trial
    Homayouni, Fatemeh
    Haidari, Fatemeh
    Hedayati, Mehdi
    Zakerkish, Mehrnoosh
    Ahmadi, Kambiz
    PHYTOTHERAPY RESEARCH, 2017, 31 (10) : 1539 - 1545
  • [28] Efficacy and safety of empagliflozin as add-on to insulin in Japanese patients with type 2 diabetes: A randomized, double-blind, placebo-controlled trial
    Sone, Hirohito
    Kaneko, Tatsuroh
    Shiki, Kosuke
    Tachibana, Yoshifumi
    Pfarr, Egon
    Lee, Jisoo
    Tajima, Naoko
    DIABETES OBESITY & METABOLISM, 2020, 22 (03) : 417 - 426
  • [29] Effects of metformin in patients with poorly controlled insulin-treated type 2 diabetes mellitus -: A randomized, double-blind, placebo-controlled trial
    Avilés-Santa, L
    Sinding, J
    Raskin, P
    ANNALS OF INTERNAL MEDICINE, 1999, 131 (03) : 182 - +
  • [30] Effect of alirocumab on postprandial hyperlipidaemia in patients with type 2 diabetes: A randomized, double-blind, placebo-controlled, cross-over trial
    Cariou, Bertrand
    Thys, An
    Oliveira, Arsenio Rodrigues
    Letertre, Marine P. M.
    Guyomarch, Beatrice
    Carpentier, Maxime
    Cannet, Claire
    Morcel, Pierre
    Ernould, Audrey
    Flet, Laurent
    Giraudeau, Patrick
    Hadjadj, Samy
    Le May, Cedric
    Croyal, Mikael
    DIABETES OBESITY & METABOLISM, 2025, : 3006 - 3016